Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Choueiri Discusses Immunotherapy in RCC

January 23rd 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Grivas on Promising Combination Therapies in Bladder Cancer

January 19th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.

Dr. Eber Discusses Patient Selection for Cytoreductive Nephrectomy in mRCC

January 18th 2019

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma.

Dr. O'Donnell on the Importance of Identifying Molecular Subsets in Urothelial Cancer

January 17th 2019

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the importance of identifying molecular subsets in urothelial cancer.

Grivas Discusses Developments in Bladder Cancer

January 16th 2019

Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.

Dr. Wright Discusses Immunotherapy in Bladder Cancer

January 15th 2019

Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.

Nivolumab/Ipilimumab Combo Approved in Europe for Frontline RCC

January 15th 2019

The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

January 14th 2019

Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.

Dr. Pal on the Clinical Utility of PD-L1 in mRCC

January 12th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the clinical utility of PD-L1 in metastatic renal cell carcinoma (mRCC).

Expert Discusses Neoadjuvant Chemo, Cystectomy in Localized Bladder Cancer

January 12th 2019

Jonathan L. Wright, MD, MS, FACS, highlights the available therapies for patients with localized muscle-invasive bladder cancer.

Dr. Figlin on Considerations for Combining TKIs and Immunotherapy in RCC

January 10th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Dr. George on Concerns With Immune-Related Adverse Events in RCC

January 10th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).

Checkpoint Inhibitors Herald New Era in Urothelial Cancer

January 9th 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

UGN-101 Shows Encouraging CR Rates in Urothelial Cancer

January 9th 2019

The investigational mitomycin formulation UGN-101 demonstrated a 57% complete response rate in patients with low-grade upper-tract urothelial cancer.

Bellmunt Addresses Immunotherapy Advances, Challenges in Bladder Cancer

January 8th 2019

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Dr. Somer on Treatment Selection Considerations in RCC

January 8th 2019

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCC

January 4th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

Treatment-Related AEs Can Require Careful Management in Patients With RCC

January 3rd 2019

Heather Greene, NP, discusses the importance of open communication between patients and providers from the onset of therapy and provided insight on the management of treatment-related adverse events in metastatic renal cell carcinoma.

Optimizing Combinations Next Challenge in mRCC

December 20th 2018

Bradley G. Somer, MD, discusses the potential of combination regimens for patients with metastatic renal cell carcinoma.